TCR T cells for KRAS-mutated cancers
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have one of these cancers that has spread: pancreatic, bile duct, colorectal, or non-small cell lung cancer.
- Your tumor must have the KRAS G12V mutation, confirmed by a special lab test.
- You must have the HLA-A*11:01 immune type, confirmed by a blood test.
- You must have tried at least one standard treatment for advanced pancreatic, bile duct, or lung cancer, or at least three for colorectal cancer.
- You must be in relatively good health with adequate organ function and not be dependent on blood transfusions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
This trial tests an experimental treatment that uses your own immune cells (T cells) that have been specially changed to attack cancer cells with a certain genetic mutation (KRAS G12D). It may be an option for people with advanced cancer that has not responded to standard treatments.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. It targets tumors with specific genetic markers (KRAS or NRAS G12D and HLA-A*11:01) to see if it can shrink or slow the cancer.
This trial tests a new treatment made from your own immune cells that are specially trained to attack cancer cells with a specific mutation called KRAS G12V. It is for people with advanced solid tumors who have run out of standard options.
This trial tests a custom immune-cell treatment made from your blood that targets the KRAS G12V change in certain cancers. It is for people with advanced cancer who have already tried standard treatments, and it may help your immune system recognize and attack tumor cells.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.